Table 2.
Univariate and multivariate analyses of progression-free survival and overall survival in patients with renal cell carcinoma.
| Progression-Free Survival | Overall Survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | |||||
| Hazard Ratio | p Value | Hazard Ratio | p Value | Hazard Ratio | p Value | Hazard Ratio | p Value | |
| Age (years) | 1.352 | 0.607 | 1.324 | 0.661 | 4.161 | 0.089 | 7.277 | 0.040 * |
| ≧65 vs. <65 | (0.429–4.264) | (0.377–4.645) | (0.806–21.479) | (1.092–48.479) | ||||
| Gender | 1.393 | 0.619 | 0.977 | 0.978 | ||||
| Male vs. Female | (0.377–5.148) | (0.189–5.055) | ||||||
| BMI (kg/m2) | 0.614 | 0.399 | 0.246 | 0.093 | ||||
| ≧24 vs. <24 | (0.198–1.906) | (0.048–1.266) | ||||||
| Hypertension | 1.111 | 0.864 | 3.599 | 0.236 | ||||
| Yes vs. No | (0.333–3.700) | (0.432–29.975) | ||||||
| Diabetes mellitus | 0.997 | 0.997 | 2.475 | 0.236 | ||||
| Yes vs. No | (0.300–3.320) | (0.553–11.084) | ||||||
| CKD stage | 1.332 | 0.667 | 1.597 | 0.577 | ||||
| ≧3 vs. <3 | (0.360–4.928) | (0.309–8.254) | ||||||
| Smoking | 1.044 | 0.943 | 0.972 | 0.973 | ||||
| Yes vs. No | (0.314–3.472) | (0.188–5.043) | ||||||
| Leukocytosis 1 | 2.871 | 0.114 | 1.367 | 0.772 | ||||
| Yes vs. No | (0.776–10.625) | (0.164–11.363) | ||||||
| Neutrophilia 2 | 2.261 | 0.238 | 3.279 | 0.193 | ||||
| Yes vs. No | (0.583–8.772) | (0.548–19.634) | ||||||
| NLR | 1.555 | 0.467 | 1.122 | 0.889 | ||||
| ≧3 vs. <3 | (0.474–5.098) | (0.224–5.632) | ||||||
| Anemia 3 | 2.343 | 0.141 | 3.136 | 0.136 | ||||
| Yes vs. No | (0.753–7.289) | (0.699–14.069) | ||||||
| MPV/PC ratio | 6.521 | 0.016 * | 5.391 | 0.044 * | 7.946 | 0.055 | 25.285 | 0.015 * |
| Low vs. High | (1.424–29.854) | (1.049–27.700) | (0.953–66.232) | (1.880–340.158) | ||||
| Histology | 0.781 | 0.711 | 1.004 | 0.996 | ||||
| Other vs. Clear cell | (0.211–2.888) | (0.194–5.181) | ||||||
| Pathological stage | 29.882 | <0.001 * | 18.261 | <0.001 * | 11.496 | 0.004 * | 5.908 | 0.045 * |
| ≧3 vs. <3 | (6.440–138.665) | (3.769–88.475) | (2.220–59.517) | (1.044–33.437) | ||||
| Tumor grade 4 | 3.705 | 0.027 * | 3.166 | 0.081 | 6.923 | 0.022 * | 6.755 | 0.050 * |
| ≧3 vs. <3 | (1.161–11.821) | (0.868–11.555) | (1.330–36.030) | (1.004–45.469) | ||||
| Intratumor Hemorrhage | 0.834 | 0.425 | ||||||
| Yes vs. No | (0.264–2.631) | 0.756 | (0.095–1.901) | 0.263 | ||||
| Intratumor Necrosis | 4.677 | 2.038 | 2.063 | |||||
| Yes vs. No | (1.023–21.375) | 0.047 * | (0.385–10.799) | 0.403 | (0.40–10.636) | 0.387 | ||
BMI = body mass index, CKD = chronic kidney disease, NLR = neutrophil-to-lymphocyte ratio, ECOG PS = Eastern Cooperative Oncology Group Performance Status; 1—leukocytosis was defined as white blood cell count > 100,000/uL; 2—neutrophilia was defined as neutrophil count > 77,000/uL. Missing data were found in 12 patients; 3—anemia was defined as Hb < 12 g/dL; 4—Fuhrman grade was not applicable in 7 patients. * indicated p value < 0.05.